Page 2 - Evidence Level News Today : Breaking News, Live Updates & Top Stories | Vimarsana

AUA 2021 2021 AUA/ASTRO/SUO guidelines on advanced prostate cancer,

AUA 2021 AUA guidelines, guideline update for non-muscle invasive bladder cancer, AUA guidelines muscle invasive bladder cancer, high-grade T1 disease, SWOG S0337 trial, intravesical gemcitabine versus saline immediately following TURBT.

Share this article Share this article RARITAN, N.J., Feb. 8, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the final analysis of the Phase 3 TITAN study, which demonstrated the continued statistically significant benefit of the addition of ERLEADA ® (apalutamide) to androgen deprivation therapy (ADT) in overall survival (OS) in patients with metastatic castration-sensitive prostate cancer (mCSPC), regardless of extent of disease, when compared to placebo plus ADT. 1 Results will be featured in an oral presentation at the American...

Share this article Share this article RARITAN, N.J., Feb. 8, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the randomized, double-blind, placebo-controlled Phase 3 ACIS study, which met the primary endpoint of radiographic progression-free survival (rPFS) with a 31 percent reduction in the risk of radiographic progression or death in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) receiving androgen deprivation therapy (ADT). Patients in the trial received either a combination of ERLEADA Â...